Abacavir-lamivudine (ABC/3TC) and tenofovir-emtricitabine (TDF/FTC) represent in the guidelines of several countries, including Italy and United States, the preferred nucleoside/nucleotide backbones of antiretroviral regimens. We assessed their profile in pregnancy using data from a national observational study.
Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women with Hiv: Laboratory and Clinical Outcomes in an Observational National Study / Floridia, Marco; Pinnetti, Carmela; Ravizza, Marina; Masuelli, Giulia; Personeni, Carlo; Sansone, Matilde; Antoni, Anna Degli; Guaraldi, Giovanni; Spinillo, Arsenio; Tassis, Beatrice; Dalzero, Serena; Liuzzi, Giuseppina; Tamburrini, Enrica. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 78:1(2018), pp. 99-104. [10.1097/QAI.0000000000001640]
Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women with Hiv: Laboratory and Clinical Outcomes in an Observational National Study
Guaraldi, Giovanni;
2018
Abstract
Abacavir-lamivudine (ABC/3TC) and tenofovir-emtricitabine (TDF/FTC) represent in the guidelines of several countries, including Italy and United States, the preferred nucleoside/nucleotide backbones of antiretroviral regimens. We assessed their profile in pregnancy using data from a national observational study.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2018_ABC-3tc and TDF-FTC.pdf
Open Access
Tipologia:
Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione
627.77 kB
Formato
Adobe PDF
|
627.77 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
